Pankaj R. Patel
Chairman & Managing Director
Cadila Healthcare Ltd.
Mr. Pankaj Patel spearheads Zydus Cadila, one of India's leading pharmaceutical groups and a global healthcare company with operations in more than 50 countries worldwide. With an experience spanning over 30 years in the Indian pharmaceutical industry, Mr. Patel combines both research and techno-commercial expertise and has published 50 research papers. He has been the guiding force behind Zydus' fast tracked growth and innovation journey. Zydus is the only Indian pharma company to launch its own patented NCE – Lipaglyn, the world's first drug to be approved for the treatment of diabetic dyslipidemia. For his entrepreneurial vision, Mr. Patel was awarded the Ernst & Young Entrepreneur of the Year Award in the Life Sciences category.
About the Company
Zydus Cadila is an innovation-led, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. From a turnover of Rs. 250 crores (1 crores = 10 million) in 1995, the group posted revenues of Rs. 6300 crores in FY13. At the Economic Times Awards for Corporate Excellence 2010, Zydus Cadila won the award for the 'Emerging Company of the Year'. The group employs over 15,000 people worldwide and is dedicated to creating healthier communities globally.
Globally, the group has a strong presence in the regulated markets of the US, Europe (France & Spain), Japan and the high profile markets of Latin America and South Africa. It has a strong presence in 25 other emerging markets worldwide. It aims to be a leading global healthcare provider with a robust product pipeline, to achieve sales of over $3 billion by 2015 and be a research-based pharmaceutical company by 2020.